INTRODUCTION
Prostate cancer is the most commonly diagnosed cancer and the third leading cause of cancer-related deaths among men in western countries. 1 Although androgen deprivation therapy (ADT), the main treatment for prostate cancer, is initially effective for most patients, the disease often recurs and becomes castrationresistant within 18 to 24 months. 2, 3 The mechanism underlying this castration-resistance remains poorly understood. 4 Previous studies in mice and humans have reported that androgen ablation may activate thymic regeneration, elevate the absolute numbers of peripheral T cells, particularly CD4 + T cells, and enhance the responsiveness of cytotoxic T lymphocytes (CTLs) to specific-antigen stimulation. [5] [6] [7] Consistently, androgen ablation was found to remove the CD4 T cell tolerance to prostate tumorrestricted antigen, which allows these cells to expand and produce effector cytokines after vaccination with prostate-specific antigen. 8 However, whether androgen ablation can trigger anti-tumor immunity still remains controversial. For example, recent studies have revealed that several types of immune cells, including T, B, NK, and myeloid cells, infiltrate into the prostate tumor microenvironment after androgen ablation, which promotes castrationresistance of prostate cancer by activating IKK-α and STAT3 in the tumor cells. 9, 10 The dual roles of immune cells in the progression of prostate cancer after ADT indicate that there might be a conversion from an anti-tumor to a pro-tumor immune response during the occurrence of CRPC. However, what drives this transition is still unknown. Phenotypic and functional plasticity is a hallmark of several types of immune cells in the tumor microenvironment, especially CD4 T helper (T H ) cells, mediated by reciprocal interactions with tumor cells. [11] [12] [13] CD4 + T cells have been traditionally classified as T H 1, T H 2, T H 17 cells, regulatory T (T reg ) cells and T follicular helper (T FH ) cells, which are differentiated by their ability to express distinct transcriptional factors that result in the production of select cytokines and chemokine receptors. 14 In particular, it has been demonstrated that CD4 + T cells can acquire characteristics of multiple CD4 + T cell subsets simultaneously or at different times and to inter-convert between distinct CD4 + T cell subsets in response to changing circumstances. [14] [15] [16] [17] [18] [19] Therefore, we hypothesized that a specific subset of CD4 + T cells might play a vital role in the transition of the immune response to tumors after castration, which induces the onset of CRPC. In this study, we performed flow cytometric analysis of blood and tumor samples in both PCa patients and mouse models after ADT and discovered the expansion of a novel population of CD4 + T cells, CD4 low HLA-G + T cells, during the development of CRPC. More importantly, we demonstrated that elimination of these specific cells dramatically inhibited the occurrence of CRPC. Thus, this study provides insight into the rational design of combination therapies involving the depletion of CD4 low HLA-G + T cells together with ADT for effective treatment of castration-resistant prostate cancer.
RESULTS

CD4
low HLA-G + T cells are expanded in PCa patients with ADT To investigate whether and which of the T cell subtypes play a crucial role during the development of CRPC, we collected blood samples from PCa patients and measured the proportions of different T cells. Flow cytometric results revealed that the percentage of CD4 + T cells but not CD8 + T cells became significantly elevated in the peripheral blood of PCa patients with ADT (PCa/ADT), compared to those without ADT (PCa) (Fig. 1a, b ; Supplementary information, Figs. S1a and S5a). Notably, a large population of CD4 low T cells appeared in the PCa/ADT patients ( Fig. 1a, c ; Supplementary information, Fig. S1b and c) and Wright staining showed that these cells displayed a spherical, rather than elongated or flattened morphology, which was a typical characteristic of CD4 + T cells from healthy donors (HD) or PCa patients (Fig. 1c) . Considering that previous studies showed that an immune-suppressive population of CD4 low T cells arises in allotransplantation, 20 B-cell chronic lymphocytic leukemia 21 and HIV, 22 we wondered whether these CD4 low T cells represent those immune-suppressive populations and examined the expression of several immunosuppression-related cell markers, such as FOXP3, CD25, HLA-G, TCRαβ and CD5 in these cells. Surprisingly, the CD4 low T cells neither expressed CD25 or FOXP3 nor up-regulated TCRαβ or CD5 ( Fig. 1d-f ; Supplementary information, Fig. S2 a-c) . Instead, the majority of these cells displayed high HLA-G expression (Fig. 1g) , suggesting that CD4 low HLA-G + T cells might be a new subset of CD4 + T cells distinct from T reg cells. In addition, flow cytometry and immunofluorescence staining revealed that CD4 low HLA-G + T cells also appeared in the tumors of PCa/ADT patients ( Fig. 1h, 
low HLA-G + T cells are associated with CRPC occurrence in PCa patients The relative proportion of CD4 low HLA-G + T cells was measured in the peripheral blood of age-and gender-matched HD (n = 10), PCa (n = 41) and PCa/ADT (n = 33) patients by flow cytometry (Supplementary information, Table S1 ). The percentage of CD4 low HLA-G + T cells was robustly higher in the PCa/ADT group (Fig. 1j) , independent of age, TNM stage and serum PSA level, as determined by univariate analyses (Supplementary information, Table S2 ). In addition, a case-control study of the same patient (Patient 18 in Supplementary information, Table S3 ) before and after ADT also showed that the frequencies of CD4 low HLA-G + T cells were significantly increased in peripheral blood after ADT, compared to those measured before ADT (Supplementary information, Fig. S5a ), echoing the results obtained from above population-based study. To explore the effect of CD4 low HLA-G + T cells on the onset of CRPC, the PCa/ADT group was first divided into two subgroups, CD4 low HLA-G + -high and CD4 low HLA-G + -low, based on the percentages of CD4 low HLA-G + T cells in peripheral blood. The cut-off value was determined by K-means clustering algorithm using SPSS19.0 (Supplementary information, Fig. S4 and Table S3 ). We then examined the correlation between disease (CRPC)-free survival (DFS) and the percentages of CD4 low HLA-G + T cells in these patients. Kaplan-Meier survival analyses showed that the patients in the CD4 low HLA-G + -high group had significantly lower DFS times than those in the CD4 low HLA-G + -low group (P = 0.0058, Fig. 1k ), indicating that patients in the CD4 low HLA-G + -high group more easily develop CRPC. Furthermore, patients in the CD4 low HLA-G + -high group had a more advanced disease, compared to those in CD4 low HLA-G + -low group, as judged by the decrease in overall survival (OS) times (P = 0.0073, Fig. 1l ). Notably though, flow cytometric data revealed that the CD4 low HLA-G + T cells appeared at 2 months and disappeared at 36 months after ADT in PCa patients (Fig. 1m) . A case-controlled study in same patients also showed that for patients in the CD4 low HLA-G + -high group (Patient 12 and 25 in Supplementary information, Table S3 ), the levels of CD4 low HLA-G + T cells before the diagnosis of CRPC were significantly higher than those after the diagnosis of CRPC (Supplementary information, Fig. S5b and c) . In contrast, for patients in the CD4 low HLA-G + -low group who had not yet been diagnosed as CRPC (Patient 20 in Supplementary information,  Table S3 ), the percentage of these cells remained at low level (Supplementary information, Fig. S5d ). These results suggested that CD4
low HLA-G + T cells were only expanded during the conversion from PCa to CRPC. Collectively, therefore, these results suggest that CD4 low HLA-G + T cells in the peripheral blood can be potentially used as an indicator for the initiation of CRPC formation, but only within three years after ADT.
low T cells are detected in CRPC mouse models To further assess the critical role of CD4 low HLA-G + T cells on the occurrence of CRPC, we used the transgenic adenocarcinoma of mouse prostate (TRAMP) mouse model, in which the oncogene SV40 Tag is expressed under the control of the probasin promoter. 23 As previously reported, 24 TRAMP mice were castrated when they were 12-week-old ( Fig. 2a) and by the age of about 24 weeks they gradually developed CRPC. This was confirmed by histopathologic analysis of the prostate, which revealed broken layers of α-SMA-positive smooth muscle cells, a significantly higher number of proliferating cells (Supplementary information, Fig. S6b and c) , and a greater incidence of tumor-draining lymph nodes (TdLNs) and distant metastasis (Supplementary information, Fig. S6d and e) , although the ratio of genitourinary (GU) tract weight to body weight (BW) showed no significant difference between castrated mice and sham-operation controls (Supplementary information, Fig. S6a ). As expected, a considerable number of CD4 low T cells were also detected in the peripheral blood and primary tumor of CRPC mice but not in those of shamoperation controls (Fig. 2b, c, f, g ). We then examined the expression of Qa2, a murine homolog of HLA-G, 25 as a potential marker for the CD4 low T cells in the peripheral blood. We found, however, that Qa2 was not only expressed by CD4 low T cells but also by CD4 + T cells isolated from control groups and CD4 -cells (Supplementary information, Fig. S8 ), suggesting that Qa2 is not a useful marker for murine CD4 low T cells. These phenomena were also verified in the ProbCre/Pten fl/fl prostate cancer model (Fig. 2d , e, h, i; Supplementary information, Fig. S7 a-d 17) and IL-4 (T H 2) expression was dramatically increased in the CD4 low HLA-G + T cells ( Fig. 3a, b ; Supplementary information, Fig. S9 c and e) , whereas the expression of other cytokines and transcriptional factors, including GATA3 (T H 2), was low ( Fig. 3a, b ; Supplementary information, Fig. S9 a- Fig. 3c, left; Supplementary information, Fig. S10 ).
We then compared the murine CD4 low T cells isolated from the peripheral blood of CRPC TRAMP mice with human CD4 low HLA-G + T cells by RNA-seq. The results showed that the expression profile of the CD4 low T cells resembled that of the CD4 low HLA-G + T cells, with a high expression of T H 17-relevant genes and IL-4 and not of typical genes of other CD4 T-cell subsets ( Fig. 3c, right;  Supplementary information, Fig. S11 ). The expression levels of typical T H 2-and T H 17-associated effector cytokines and transcriptional factors in the peripheral blood CD4 low T cells from CRPC TRAMP mice were also analyzed by RT-PCR and intracellular flow cytometry. We found that the expression level of IL-17A, ROR-γt and IL-4 but not GATA3 was dramatically higher in CD4 low T cells than in CD4 + T cells from the wild-type and PCa groups ( Fig. 3d , e; Supplementary information, Fig. S12a, c) . These results were also verified in the ProbCre/Pten fl/fl prostate cancer mouse model ( Fig. 3f, g; Supplementary information, Fig. S12b ).
To further confirm the characterization of intratumoral CD4 low HLA-G + T cells in PCa/ADT patients, the expression levels of T H 2-and T H 17-relevant effector cytokines and key transcriptional factors in CD4 low HLA-G + T cells isolated from primary tumors of PCa/ADT patients were measured by RT-PCR. As shown in the,Supplementary information Fig. S13a the expression levels of IL-4, IL17A and RORγt but not GATA3 were significantly increased in these cells compared to those in CD4 + T cells from 
low T cells are essential for the occurrence of CRPC To investigate the role of CD4 low T cells in the onset of CRPC, we used a CD4-neutralizing antibody to deplete CD4 low T cells during carcinogenesis of castrated TRAMP mice. As our flow cytometric analysis showed that CD4 low T cells arise only at an early stage of CRPC formation (appearing at 8 weeks and disappearing at 16 weeks after castration; Supplementary information, Fig. S14 ), we injected anti-CD4 antibody every 3 days at 8 weeks after castration for a total of four times (Fig. 4a) . This effectively depleted the CD4 low T-cell population (Supplementary information, Fig. S15a ). Histopathological analysis revealed that, compared to the isotype antibody controls, depletion of CD4 low T cells resulted in only high-grade prostatic intraepithelial neoplasia (PIN), but not invasive carcinomas ( Fig. 4b; Supplementary  information, Fig. S15b ), and significantly reduced the incidence of TdLN, liver and lung metastasis in these mice ( Fig. 4c-e;  Supplementary information, Fig. S15c ). Thus, these results showed that depletion of CD4 low T cells could effectively inhibit the occurrence of CRPC. In sharp contrast, depletion of CD4 + T cells using this anti-CD4 antibody in TRAMP mice without castration displayed little adverse effects on the progression of prostate cancer ( Fig. 4b- low T cells into castrated TRAMP mice to confirm that these cells play a key role in CRPC onset. To this end, we intravenously injected CD4 low T cells isolated from the peripheral blood of CRPC TRAMP mice into twoweek castrated TRAMP mice every 2 weeks for a total of three times (Fig. 4j) and confirmed the infiltration of CD4 low T cells into the tumor microenvironment (Supplementary information,  Fig. S17a ). Histopathological analyses showed that, compared to control groups, castrated TRAMP mice with adoptive transfer of CD4 low T cells developed more aggressive cancer ( Fig. 4k;  Supplementary information, Fig. S17b ) and exhibited a significantly elevated incidence of tumor metastasis ( Fig. 4l-n low TAM frequencies in primary tumor of control and anti-CD4-treated recipient mice. e, f Quantification of (d) (n = 6, every group). g Experimental approach to evaluate the roles of CD4 low T cells in modulating the properties of TAMs to promote androgen-independent growth of PCa cells. h Cell proliferation of TRAMP-C1 cells treated with 20 μM Casodex in the cocultures as in (g) by CCK8 assay (n = 3, every group). i Quantification of the number of macrophages that have migrated through the membrane of insert in the co-cultures as in (g) (n = 3, every group). Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 by t tests (b, c, e, f, h, i) depletion of CD4 low T cells in the castrated TRAMP mice by treatment with anti-CD4 antibody, the two myeloid cell subsets essentially disappeared (Fig. 5d-f 31, 32 and more importantly our flow cytometric data showed that neither of the two myeloid cell subsets expressed Gr-1, indicating that these cells are TAMs but not MDSCs (CD11b Fig. S18a) . Together, this implies that CD4 low T cells might affect the activity and/or accumulation of TAMs in castrated TRAMP mice. Notably, the increase of CD11b hi F4/80 low TAMs in the primary tumors of CRPC TRAMP mice was not statistically significant (Fig. 5c) , suggesting that CD4 low T cells may mainly modulate the properties of CD11b low F4/80 hi TAMs. To further confirm the positive effects of CD4 low T cells in modulating the pro-tumorigenic activities of TAMs, we established an in vitro coculture system with CD4 low T cells, bone marrow-derived macrophages and TRAMP-C1 cells, the last of which are androgen-dependent prostate tumor cells derived from TRAMP mice 33 ( Fig. 5g) . We found that, in the presence of macrophages, CD4 low T cells had higher ability to induce androgen-independent growth of TRAMP-C1 cells than CD4 + T cells (Fig. 5h) . Notably, CD4 low T cells or macrophages alone did not exhibit an ability to induce androgen-independent growth of TRAMP-C1 cells (Fig. 5h) . To further investigate the effects of CD4 low T cells on the polarization of TAMs, macrophages were collected from the coculture system and examined by flow cytometry. We found a significant increase in CD206 (M2 macrophages) but not CD80 (M1 macrophages) expression in CD4 low T-macrophage co-cultures, compared to those in CD4 + T-macrophage co-cultures (Supplementary information, Fig. S18b ). This suggests that CD4 low T cells induce M2 polarization of macrophages. We then measured the number of macrophages that had migrated through the membranous insert in the co-culture system. We found that a greater number of cells migrated in the CD4 low T-macrophage cocultures than in the CD4 + T-macrophage co-cultures (Fig. 5i) . Taken together, these findings indicate that CD4 low T cells promote androgen-independent growth of prostate cancer cells by modulating the activities and accumulation of macrophages.
To further explore the mechanism by which CD4 low T cells modulate the properties of macrophages, IL-4 and/or IL-17 neutralizing antibodies were added into the co-culture system (Fig. 5g) . This revealed that neutralization of IL-4, but not IL-17, completely abrogated the androgen-independent growth of TRAMP-C1 cells (Fig. 5h) and M2 polarization of macrophages in the co-culture system (Supplementary information, Fig. S18b ). In contrast, antibody blockage of IL-17 inhibited the migration of macrophages in the co-culture system (Fig. 5i) . Thus, CD4 low T cells regulate the activities and migration of TAMs by IL-4 and IL-17 to promote androgen-independent growth of prostate cancer cells. and CD4 low CD8 low cells accumulated in the thymuses of CRPC mice compared to controls ( Fig. 6a; Supplementary information,  Fig. S19b) . Furthermore, we found that CD4 low CD8 low and CD4 low CD8 -cells began to appear at 8 weeks and disappeared at 16 weeks after castration (Supplementary information,  Fig. S19c ). This is similar to the times at which the CD4 low T cells appeared and disappeared in the peripheral blood (Supplementary information, Fig. S14 ). These results indicate that anomalous differentiation of thymocytes contributes to the generation of CD4 low T cells in CRPC mice. These phenomena were also confirmed in the ProbCre/Pten fl/fl prostate cancer mouse model ( Fig. 6b; Supplementary information, Fig. S19d ).
To determine whether the aberrant differentiation of thymocytes was induced by an androgen blockade alone, the frequencies of CD4 low CD8 low and CD4 low CD8 -thymocytes in castrated control wild-type mice were examined by flow cytometry. The results showed that there was no significant difference in the percentages of these cells between castrated and sham-operation control groups (Supplementary information,  Fig. S20a) . Moreover, CD4 low T cells also did not expand in peripheral blood of castrated control wild-type mice (Supplementary information, Fig. S20b) . Together, these results indicate that an androgen blockade alone does not induce the anomalous differentiation of thymocytes in CRPC mice. Several biochemical signals have been shown to play roles in thymocyte differentiation. [34] [35] [36] In particular, prostaglandin E 2 (PGE 2 ) has been demonstrated to induce CD4 -CD8 -double negative (DN) cells to differentiate into CD4 low CD8 low cells in vitro. 37 We therefore investigated the role of PGE 2 in this unusual thymocyte differentiation. First, we examined if the synthesis of PGE 2 was upregulated following ADT in these mice and in PCa patients. We found that PGE 2 levels were substantially increased in the serum of CRPC TRAMP and ProbCre/Pten fl/fl mice and PCa/ADT patients ( Fig. 6c-e) . Secondly, we determined whether PGE 2 exerted a direct role in thymocyte differentiation. CD4 -
CD8
-DN cells isolated from the thymuses of wild-type mice were induced to develop into mature T cells in the presence of autologous thymic stromal cells and IL-7 for 5 days in culture, into which different concentrations of PGE 2 were added. PGE 2 promoted the accumulation of CD4 low CD8 low and CD4 low CD8 -cells in a dosedependent manner, implying that PGE 2 might indeed contribute to the abnormal differentiation of thymocytes in CRPC mice ( Fig. 6f; Supplementary information, Fig. S21a and b) . It has been demonstrated that EP2 and EP4 are major PGE 2 receptors in T cells. 38 Furthermore, our results showed that the transcriptional level of EP2 but not EP4 was dramatically increased in thymocytes of CRPC mice (Fig. 6g) . To determine which receptor(s) primarily mediates PGE 2 -induced, aberrant T cell differentiation, we examined the effects of adding an EP2 antagonist (AH6809) and/or EP4 antagonist (GW627368X) into the culture system described above. We found that the EP2 antagonist significantly inhibited the effect of PGE 2 on T cell differentiation; the EP4 antagonist had a synergistic function when applied together with EP2 antagonist; whereas the EP4 antagonist alone was ineffective ( Fig. 6f; Supplementary information, Fig. S21a and b) .
Consistent with a defect in thymocyte differentiation, the naïve CD4 + T cells also exhibited an unusual phenotype of CD4 low CD62L + in the CRPC mice ( Fig. 6h; Supplementary  information, Fig. S21c ). To explore possible effects of PGE 2 on the polarization of CD4 + T cells, naïve CD4 + T cells were isolated from spleens of TRAMP and CRPC mice and were induced under T H 2-polarizing conditions as previously reported. 26 This has been showed to mimic the in vivo environment in PCa (Fig. 3a, b, d-g Fig. S21d-f) . A recent study reported that PGE 2 could up-regulate IL1R1 and IL23R expression in CD4
+ T cells to promote T H 17 cell differentiation. 38 Using RT-PCR, we found that IL23R expression was dramatically enhanced along with T cell polarization by PGE 2 under the T H 2-polarizing conditions (Fig. 6j) . Moreover, in the presence of IL-23, PGE 2 significantly enhanced the proportion of IL-4 + IL-17A + CD4 + T cells induced from CD4 low naive T cells whereas IL-23 alone had no effect on this polarization ( Fig. 6i;  Supplementary information, Fig. S21e, f) . To explore which receptor(s) of PGE 2 play a dominant role in the regulation of this polarization, EP2 and/or EP4 antagonists were added into the culture system described above. We found that the EP2 antagonist significantly decreased the proportion of IL-4 + IL-17A + CD4 + T cells polarized from naïve CD4 low T cells whereas the EP4 antagonist enhanced the inhibition of T cell polarization into IL-4 + T H 17 cells when used together with EP2 antagonist, although the EP4 antagonist alone had no effect ( Fig. 6k; Supplementary information, Fig. S21g, h) . Together, these findings demonstrated that PGE 2 induces the abnormal differentiation of thymocytes and promotes the polarization of naïve CD4 low T cells into IL-4
+ T cells by activating PGE 2 -EP2 signaling and upregulating IL23R expression (Supplementary information, Fig. S22 ).
Celecoxib abrogates CRPC by inhibiting the generation of CD4 low T cells Next, we determined whether depletion of CD4 low T cells by suppressing PGE 2 signaling was able to inhibit occurrence of CRPC. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib and aspirin, can inhibit PGE 2 synthesis by suppressing the activity of COX-2. 39, 40 There is also evidence suggesting that NSAIDs have chemo-preventive roles in colon cancer and PCa. [39] [40] [41] [42] [43] Fig . 6 The formation of CD4 low T cells is induced from DN thymocytes via PGE 2 -EP2 signaling after castration. a, b CD4 low CD8 low and CD4 low CD8 -T-cell frequencies in thymus of CRPC TRAMP (a) and ProbCre/Pten fl/fl (b) mice. c PGE 2 level in serum of CRPC TRAMP mice, shamoperation controls and wild-type mice (n = 10, every group). d PGE 2 level in serum of CRPC ProbCre/Pten fl/fl mice, sham-operation controls and wild-type mice (n = 6, every group). e PGE 2 level in serum of healthy donors (n = 15), PCa patients (n = 19) and PCa/ADT patients (n = 15). low T cells from spleen of CRPC TRAMP mice cultured as in (i) with/without EP2 and/or EP4 antagonists. Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 by t tests (c-e, g, j) However, a recent clinical trial demonstrated that administration of celecoxib 400 mg twice daily for up to 1 year is ineffective for high-risk PCa patients initiating ADT. 44 We thus wondered whether blocking the synthesis of PGE 2 at around 8 weeks after castration, when CD4 low T cells begin to appear in the thymus, would produce any beneficial effects in PCa treatment (Fig. 7a) . Pathological analysis revealed that celecoxib treatment starting at 8 weeks after castration (celecoxib Week 8 ) led to only high-grade PIN and a decreased number of proliferative cells (Fig. 7b, c) , with no invasive carcinomas and a dramatically reduced incidence of TdLN, liver and lung metastasis ( Fig. 7d-f ; Supplementary information, Fig. S23a ) compared to untreated controls. However, celecoxib treatment at 1 week after castration (celecoxib Week 1 ) unexpectedly enhanced tumor cell invasion and proliferation (Fig. 7b, c) . These results were confirmed by flow cytometric data, which showed that the percentage of CD4 low T cells was significantly decreased in the celecoxib week 8 treatment group whereas the celecoxib week 1 treatment failed to inhibit the accumulation of CD4 low T cells ( Fig. 7g ; Supplementary information, Fig. S23b-e) . Importantly, the celecoxib week 8 but not celecoxib week 1 treatment group showed remarkably longer survival times than the untreated controls (Fig. 7h) .
To examine the possible source of the adverse effects of the celecoxib week 1 treatment, the level of PGE 2 in the serum and EP2 expression in CD4 + T cells isolated from peripheral blood during the celecoxib treatment were examined by ELISA and RT-PCR, respectively. The results showed that the levels of PGE 2 were indeed decreased at about 3 weeks after drug treatment, although these levels slightly increased later (Fig. 7i) whereas EP2 expression gradually increased starting from 5 weeks after celecoxib treatment (Fig. 7j) . These results suggest that a compensatory elevation of EP2 expression in T cells, which reactivates PGE 2 -EP2 signaling to promote the generation of CD4 low T cells (Fig. 7g) , might explain the adverse effects of celecoxib week 1 treatment. Thus, collectively, these results indicate that CD4 low T cells could be used as specific indicators of the effectiveness of celecoxib treatment for PCa with ADT.
DISCUSSION
Over the past several decades, a number of studies have attempted to apply immunotherapy to improve the overall survival in prostate cancer mouse models and patients with ADT. 45 However, the therapeutic outcomes have not been particularly positive so far. In this study, we observed that a novel population of CD4 low HLA-G + T cells expands in both PCa patients and mouse models at an early stage of CRPC. This expansion is correlated with CRPC occurrence in patients and essential for CRPC onset in mouse models. Functional analysis demonstrated that these cells are IL-4-expressing T H 17 cells, which promote androgen-independent growth of PCa cells by modulating the properties of TAMs. By blocking the generation of CD4 low HLA-G + T cells, the onset of CRPC is prevented. Thus, our experiments suggest a new therapeutic approach to overcome castrationresistance of prostate cancer.
Having demonstrate the importance of the CD4 low HLA-G + T cell population in the onset of CRPC, we have provided significant insight into the mechanisms responsible for the generation of these cells. A previous study showing that PGE 2 could induce DN cells isolated from the thymus to differentiate into CD4 low CD8 low cells in vitro 37 inspired our investigation of a possible role of PGE 2 in the production of CD4 low HLA-G + T cells. Indeed, we obtained several results that directly support this hypothesis. First, we found that expression levels of PGE 2 are significantly increased after androgen ablation in both PCa patients and mouse models. Second, our studies also detected the expansion of CD4 low CD8 low and CD4 low CD8 -cells in the thymus of PCa mouse models after castration. Third, PGE 2 promotes DN thymocytes to differentiate into CD4 low cells in a dose-dependent manner, which is significantly inhibited by an EP2 antagonist in an in vitro culture system. Furthermore, administration of celecoxib, a PGE 2 synthesis blocker, dramatically prevents the production of CD4 low CD8 low and CD4 low CD8 -thymocytes as well as peripheral CD4 low T cells in PCa mouse models after androgen ablation. Thus, in total, these results show that PGE 2 -EP2 signaling induces an aberrant differentiation of thymocytes from DN cells to CD4 low cells, contributing to the generation of CD4 low HLA-G + T cells. It should be noted that although PGE 2 has been shown to have multiple effects in modulating the pro-tumor properties of immune cells in the tumor microenvironment, in addition to a direct role on tumor cells, 46 its effect on thymocyte differentiation has been rarely mentioned. To the best of our knowledge, the current study is the first report to demonstrate that PGE 2 can induce abnormal differentiation of thymocytes from DN cells to CD4 low cells during the development of prostate cancer after ADT, which is responsible for the generation of CD4 low HLA-G + T cells. Supporting data for this model also come from other previous studies. For instance, (1) higher levels of PGE 2 are not only observed in the present study but have also been seen in many other cancer types, including colorectal cancer, breast cancer and gastric cancer. 46 (2) There is a close correlation between sex steroids and the rejuvenation of the thymus. 47 (3) Androgen ablation has a positive effect on the activation of thymic regeneration.
6,7,47 (4) T H 17 cells have been seen to expand in the tumor microenvironment via PGE 2 and PGE 2 -induced upregulation of IL-23R in breast cancer. 38, 48 Therefore, it is likely that in response to the aberrant elevation of PGE 2 , the thymocytes adopt a different program to differentiate into an unusual subtype of T cells.
Our findings indicate that application of celecoxib starting at different time points after ADT may produce distinct therapeutic outcomes. On the one hand, celecoxib treatment starting at eight weeks after castration, when CD4 low HLA-G + T cells are detected, dramatically inhibits the occurrence of CRPC, and more importantly prolongs survival times in PCa mouse models. On the other hand, administration of celecoxib immediately following ADT leads to the failure of prostate cancer therapy, with enhanced tumor cell infiltration and proliferation as well as failure to abrogate the production of CD4 low HLA-G + T cells in mouse models. A similar phenomenon has been reported in a recent clinical trial for prostate cancer: namely, application of celecoxib and ADT simultaneously does not produce better clinical outcomes than ADT alone. 44 A possible explanation for the difference may be that the long-term use of celecoxib activates a compensatory mechanism to enhance PGE 2 synthesis and/or upregulate the expression of proteins in downstream signaling of PGE 2 . Support for this notion comes from the current study in which long-term use of celecoxib in the PCa mouse models led to compensatory elevation of EP2 expression in T cells, which reactivates PGE 2 -EP2 signaling to promote the generation of CD4 low HLA-G + T cells. Similar observations are also reported in intestinal tumors, where long-term use of celecoxib has been Fig. 7 Celecoxib abrogates progressive development of CRPC by inhibiting the generation of CD4 low T cells. a Experimental approach to evaluate the curative effect of celecoxib treatment on prostate cancer after ADT. wks, weeks. b H&E and immunohistochemistry microscopy of prostate showing tumor progression following drug treatment as in (a). Scale bar, 100 μm. c Quantification of Ki67 staining in the prostate gland (means of 10 HPF ± SEM) for week 1, week 8 drug-treated and control subgroups (n = 6, every group). d-f Incidence of TdLN (d), liver (e) and lung (f) metastasis following drug treatment as in (a) (n = 6, every group). g CD4 low CD8 low and CD4 low CD8 -thymocyte frequencies and CD4 low T-cell frequencies in peripheral blood and primary tumors of castrated TRAMP mice following drug treatment as in (a). h Overall survival of week 1, week 8 drug-treated and control subgroups (n = 10, every group). The endpoint of survival analysis is 48 weeks. i, j PGE 2 level in serum (i) and EP2 expression in peripheral blood CD4 + T cells (j) following drug treatment as in (a) (n = 5, every group). Mean ± SEM (c, i, j). *P < 0.05, **P < 0.01, ***P < 0.001 by t tests (c, i, j), χ 2 test (d-f) and log-rank analysis (h)
shown to produce significantly higher levels of PGE 2 and reactivation of PGE 2 -associated signaling pathways in tumors and normal tissues. 49 Taken together, these results highlight the importance of timing in implementing celecoxib treatment and further, demonstrate that CD4 low HLA-G + T cells can be used as an indicative marker of therapeutic efficacy in celecoxib treatment on prostate cancer after ADT.
Several mechanisms underlying androgen-independent growth of prostate cancer cells have been demonstrated, including amplification of the androgen receptor (AR) gene, mutations in the AR gene and AR-independent signaling. 50, 51 Although neuroendocrine prostate cancer only represents a small portion of initially diagnosed prostate cancer, accumulating evidence has suggested that neuroendocrine differentiation (NED) can be induced by ADT. Further, NED is associated with cancer recurrence and poor prognosis, suggesting that NED is one of mechanisms associated with CRPC formation. 52, 53 Thus, although the TRAMP model is a neuroendocrine small cell prostate cancer model, it has its value for the study of the development and biological characteristics of CRPC in humans. More importantly, in our study we used both TRAMP and ProbCre/Pten fl/fl mice to confirm our findings obtained from PCa patients and found that CD4 low T cells appeared after castration in both of these mouse models.
In summary, we have demonstrated that a novel population of CD4 low HLA-G + T cells induced by PGE 2 is expanded in PCa patients and mouse models after ADT, which impairs the host immune surveillance and converts the tumor microenvironment into a pro-tumor state. Elimination of this population by celecoxib may produce clinical benefit for prostate cancer patients after ADT. Thus, the proper combined use of celecoxib and ADT may sustain the anti-tumor immune response, pointing to a new therapeutic avenue for better prostate cancer management (Supplementary information, Fig. S24 ).
MATERIALS AND METHODS
Study design
This was a preclinical study of CD4 low HLA-G + T cells as a prognostic factor and therapeutic target for CRPC. We used blood and tumor samples of PCa patients to determine whether CD4 low HLA-G + T cells were specifically expanded in PCa patients after ADT and analyzed the correlation between proportions of CD4 low HLA-G + T cells and the prognosis in PCa/ADT patients. To further study the characteristics of these cells, multiple CRPC murine models were constructed. CD4 low HLA-G + T cells were first defined as IL-4-expressing T H 17 cells in both PCa patients and mouse models by qPCR, intracellular flow cytometry and RNA-seq analysis. And subsequent cell depletion studies and adoptive transfer assays were performed to test if these cells were essential for the formation of CRPC. To analyze the function of CD4 low HLA-G + T cells, an in vitro co-culture system comprising CD4 low T cells, macrophages and TRAMP-C1 cells was established and the proliferation of TRAMP-C1 cells after androgen ablation, the polarization of macrophages, and the numbers of migrated macrophages were examined. To explore the effects of PGE 2 on the production of CD4 low HLA-G + T cells, DN thymocytes and CD4 low naïve T cells were cultured in the presence of PGE 2 in vitro and the percentages of CD4 low thymocytes and IL-4 + IL-17A + CD4
+ T cells were measured by flow cytometry, respectively. Finally, we administrated celecoxib, a synthesis blocker of PGE 2 , and combined with ADT in PCa mouse models that were refractory to ADT alone. Mice were randomized to different treatment groups on the basis of histopathologic features to make sure that all castrated mice in the experiments were formed CRPC. The number of samples is stated in each figure legend and all experiments were performed independently at least three to five times. All data were analyzed and outliers were not excluded. 
Animals
All animal studies were reviewed and approved by the institutional Animal Care and Use Committee of Shanghai Jiao Tong University. All mice were maintained in pathogen-free conditions and cared for in compliance with ethical regulations at Renji Hospital. TRAMP, probCre and Pten fl/fl mice were introduced from Jackson laboratory. Mice were castrated at 12-weeks of age and sacrificed 12 weeks post-castration unless indicated otherwise. Prostates, TdLNs, livers and lungs were collected for H&E and immunohistochemistry staining. The diagnosis of tumor metastasis was made independently by two pathologists. Central and peripheral lymphoid organs were collected for flow cytometry. The genetic backgrounds of all mice used in this study were C57BL/6. Cells TRAMP-C1 murine prostate adenocarcinoma cells were purchased from the American Type Culture Collection (ATCC).
Immune cell isolation Thymuses were mechanically dissociated and strained through a 40 μm nylon mesh to produce a single cell suspension. After RBCs were lysed, cells were stained with CD4 and CD8 antibodies, and CD4
−
CD8
− DN or CD4 + CD8 + DP cells were sorted by flow cytometry. For thymic stromal cells, thymuses were digested into single cells using collagenase type IV (0.5 mg/mL), DNase I (2 U/ mL) for 2 h at 37°C. The dissociated cells were collected and cultured with RPMI 1640 medium for 2 days. The suspended cells were removed and remaining cells cultured in RPMI 1640 medium for another 5 days. For naive CD4 + T cells, cells were isolated with a CD4 +
CD62L
+ T-cell isolation kit II (Miltenyi Biotec). For tumorinfiltrating leukocytes (TILs), tumors were digested into single cells with collagenase type IV (0.5 mg/mL), hyaluronidase (10 U/mL) and DNase I (0.01 mg/mL) for 2 h at 37°C. The dissociated cells were collected, lysed with RBC lysis buffer, and then incubated with CD4 monoclonal antibody. For peripheral blood CD4 + T cells, blood samples were subjected to density centrifugation using Ficoll-hypaque solution to isolate mononuclear cells. After RBCs were lysed, cells were incubated with CD4 antibody and then sorted by flow cytometry.
Cell depletion study Male castrated TRAMP and ProbCre/Pten fl/fl mice were depleted of CD4 low T cells by intraperitoneal injection of a 250 μg CD4-neutralizing antibody beginning at 8 weeks post-castration and continuing every 3 days for a total of four times. Control mice were injected intraperitoneally with an isotype control antibody, according to the same dosing schedule. The efficiency of CD4 low Tcell depletion was verified by flow cytometry. Anti-CD4 antibody (BioXCell, in VivoPlus Rat IgG2b anti-mouse CD4, clone LTF-2, BP0003-1) and isotype control antibody (BioXcell, in VivoPlus Rat IgG2b Isotype control, clone LTF-2, BP0090) were used. Mice were sacrificed at 12 weeks post-castration. Prostates, TdLNs, livers and lungs were collected and performed H&E and immunohistochemistry staining. The progression of primary tumor and incidence of TdLN, liver and lung metastasis were analyzed.
Adoptive transfer assay CD4 low and CD4 + T cells were isolated from peripheral blood of 24-week-old CRPC TRAMP mice and sham-operation controls, respectively, as previously described. Next, a total of 1 × 10 6 CD4 low or CD4 + T cells were activated with 3 μg/mL anti-CD3 and 3 μg/ml anti-CD28 antibodies for 6 h. Castrated TRAMP mice received an intravenous injection of 1 × 10 6 CD4 low T cells beginning at 2 weeks after castration and continuing every two weeks for a total of three times. Control groups were injected intravenously with 1 × 10 6 CD4 + T cells or a same volume of PBS, according to the same dosing schedule. All mice were sacrificed at 8 weeks post-castration, except for those used in cell tracking assays. Prostates, TdLNs, livers and lungs were collected and performed H&E and immunohistochemistry staining. The progression of primary tumors and incidence of tumor metastases were analyzed.
If cell tracking was required, CD4 low and CD4 + T cells were labeled using a Qtracker ® 565 cell labeling kit (ThermoFisher) and then injected intravenously into castrated TRAMP mice. Mice were sacrificed 24 h after cell injection. The fluorescence of prostate sections was monitored on a Leica DM2500 fluorescence microscope.
CD4
low T cell-macrophage-TRAMP-C1 cell co-cultures CD4 low T cells were isolated from primary tumors of CRPC TRAMP mice as previously described. Whole bone marrow cells were isolated from C57BL/6 mice. Macrophages were generated by incubating whole bone marrow cells in macrophage colonystimulating factor (M-CSF, 10 ng/mL) for 7 days and harvesting the adherent fraction. For co-culture assays, 5 × 10 4 macrophages and equal number of TRAMP-C1 cells were added into the upper and bottom chambers of a 24-well Transwell apparatus (Corning), respectively. After 6 h culture, 2.5 × 10 5 CD4 low T cells activated by a leucocyte activation cocktail (BD Biosciences) were added into the bottom chamber of the Transwell apparatus. After 24 h of coculture, CD4 low T cells and macrophages were removed and then TRAMP-C1 cells were treated with 20 μM Casodex (Sigma) for 3 days. Cell proliferation of TRAMP-C1 cells was measured by CCK8 assay according to the manufacturer's directions (MedChemExpress). To analyze the polarization of macrophages, macrophages in the co-culture system were collected and examined by flow cytometry using anti-CD80 and anti-CD206 antibodies (ebioscience). To examine the migration of macrophages, cells passing through the membrane of the insert after co-culture were stained by haematoxylin and quantified by counting the number of cells in five high-power fields (HPF) per well. For blocking experiments, 10 μg/mL anti-IL-4 and/or anti-IL-17 were used.
In vitro differentiation of CD4 low thymocytes CD4 -CD8 -DN cells and thymic stromal cells were isolated from thymus of C57BL/6 mice as described above. For CD4 
low T-cell polarization Naïve CD4 + T cells were isolated from spleen of CRPC TRAMP mice and sham-operation controls as previously described. A total of 1 × 10 6 naive CD4 + T cells were activated with 1 × 10 7 T-depleted splenocytes as APC with 3 μg/mL anti-CD3 and 3 μg/mL anti-CD28 antibodies. The activated cells were cultured under T H 2-polarizing conditions (10 ng/mL IL-4 and 10 μg/mL anti-IFN-γ) for 3 days. Immunofluorescence 5-μm sections of primary prostate carcinoma frozen in OCT were fixed in 4% paraformaldehyde, and blocked with 10% normal donkey serum before application of primary antibodies as follows: CD4 (ab133616, Abcam) at a dilution of 1:200, HLA-G (ab7758, Abcam) at a dilution of 1:100. All secondary antibodies were raised in donkey. CD4 was detected using anti-rabbit IgG conjugated to AlexaFluor 594 (Invitrogen), while HLA-G was detected by antimouse IgG conjugated to AlexaFluor 488 (Invitrogen). Slides were mounted using prolong TM Gold antifade reagent with DAPI (Invitrogen) and imaged using a Leica DM2500 fluorescence microscope.
In vivo treatment Castrated TRAMP mice were assigned into three experimental groups: a control group (fed with normal food), a celecoxib week 1 treatment group, and a celecoxib week 8 treatment group. Celecoxib was milled into mouse chow at a concentration of 100 mg/kg. For the celecoxib week 1 treatment group, mice were treated with celecoxib at 1 week after castration; the celecoxib week 8 treatment group were treated with celecoxib at 8 weeks after castration. All mice were sacrificed at 12 weeks post-castration, except for those castrated TRAMP mice treated with celecoxib and subject to survival analysis (The endpoint of survival analysis was 48 weeks). CD4 + T cells were isolated from peripheral blood and the expression of EP2 was measured by RT-PCR. The percentages of CD4 low T cells in thymus, peripheral blood and primary tumor were determined by flow cytometry. Tumors, TdLNs, livers and lungs were collected for H&E and immunohistochemistry to analyze the development of tumor.
RNA sequencing
The RNA quality and integrity were analyzed by Qubit 2.0 (Life Technologies, USA) and Bioanalyzer 2100 (Agilent, Germany). For library preparation, 3 μg total RNA was captured by NEBNext Oligo d(T) 25 beads (NEB, USA), sheared to give fragments of approximately 250 bp, and reverse transcribed using NEBNext RNA first and second Strand Synthesis Module (NEB, USA). The products were end-repaired, A-tailed and ligated to Illumina sequencing adapters and amplified by PCR. The sequencing library were qualified by Qubit 2.0 (Life technologies, USA) and Bioanalyzer 2100 (Agilent, Germany) and then sequenced using an Illumina Hiseq X-Ten with 2 × 150 bp paired-end sequencing, controlled by Hiseq Control Software (HCS). Raw sequence reads were initially examined using FastQC for quality control. Raw reads were processed to trim low quality sequences and adapters using Trimmomatic. Clean reads were then mapped to hg19 for human and mm9 for mouse using STAR, and only uniquely mapped reads were kept. Read counts were calculated by HTSeqcount. Differential expression analysis was performed using DESeq2.
Statistical analysis Statistical analysis of the data was performed using the Student's t-test and results were presented as mean ± SEM unless indicated otherwise. P values < 0.05 were considered significant. Significant differences in survival curves were calculated using the log-rank test. Correlation analysis between percentages of peripheral blood CD4 low HLA-G + T cells and pathological parameters of PCa/ADT patients was conducted by logistic regression. Unsupervised Kmeans clustering of PCa/ADT patients was performed using SPSS 19.0, K = 2. The statistical test of incidence of tumor metastasis was performed by χ 2 test using SPSS19.0.
Data and materials availability
The RNA-seq dataset is available at the GEO database, accession number GSE109844. Detailed materials and methods are available in Supplementary information, Data S1.
